StreetInsider.com News Articles

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)-- Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof”. This application contains claims

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0500

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the “Bankers”) to begin the process of raising funds to advance the development of the Company’s patented innovative pharmaceutical candidate, Conjugated Psilocin™. Lobe previously announced the creation of Alera Pharma, Inc. as an operating company to develop the drug candidate.

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0500

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)-- Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma (“Alera or Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™

Wed, 02 Oct 2024 07:30:00 -0500

U.S. Patent Office issues patent number 12,102,616
Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders

Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.